Prevention of male sexual health passes from first to last palpation or self-palpation of the testicles. A simple signal to carry out that might save the lives of many people, even young people. Testicular cancer affects men between 15 and 45 years of age and in current years has recorded a 12% increase with an estimated increase of 30% by 2025. Fortunately, its humanity rate is rather low, maximum 20 %, but it could contain even additional if we managed to get a clear and accurate message about the need to prevent the disease.
Unfortunately, there is still a state of mind on this aspect whereby we turn to the doctor only when we are faced with a symptom, men try to live up to the idea of an indestructible virility from different points of view and that of the avoidance of sexual health, in its more than a few aspects, it is becoming more common in old age, the prostate is known to be kept under manage, but it still cannot pass the importance of controls in teenage years and adulthood.
The state of affairs today is slightly more improved, as men are worried for their sexual potency and the slightest indication of the dreaded erectile dysfunction can send them for a checkup at a urologist. But did you know that the drugs used for ED treatment can help fight ontological diseases, prostate tumors of benevolent nature and indirectly save lives from side to side urging a man to have an appointment with a doctor who can detect the signs of an illness early on?
With the endorsement of sildenafil, in the 90s, in the treatment of erectile dysfunction, an enzyme, phosphodiesterase type 5 (PDE5) became popular. Later it was exposed that selective inhibition of this enzyme could also be exploited in other areas such as pulmonary arterial hypertension and Reynaud’s condition. Now, however, it is being exposed that these drugs can also be useful in oncology. For example, if linked with immunomodulators, drugs so in vogue now in anticancer therapies, they add to their immunomodulatory activity while if associated with cardiotoxic chemotherapy, such as doxorubicin, they decrease its cardiotoxicity.
Thanks to their ability to conquer the blood-brain barrier, they could find request in glioblastoma, as a therapeutic enhancer of anticancer drugs.
Doing a quick look for (PDE5 inhibitors and cancer) on the Pub Med search engine, one can state that a lot of works published in the last few months come out. This confirms the new clinical evidence, in the oncological field, of the discriminating cGMP phosphodiesterase inhibitors type 5 (PDE5), in meticulous sildenafil (Fildena 100), vardenafil (Levitra), and tadalafil (Vidalista 20). Little information, however, can be established in this are on the latest accepted of the series, avanafil (Spedra). It is a repositioning further than their first indication, erectile dysfunction, and the second sign, pulmonary arterial hypertension.
This work reviews the three major PDE5 inhibitors and their clinical indication. It all started in the 1980s; with an investigation by Pfizer on the use of one of these inhibitors, sildenafil, in angina pectoris. The clinical trial begins in 1991. The unexpected “side effects” observed in male patients enrolled in the study persuaded Pfizer to study this product in erectile dysfunction.
Some of the common prostate cancer medicine and drugs used for the hormone therapy treatment of prostate cancer are Leuprolide Acetate Depot 11.25mg Injection which is given intravenously and another medication such as Flutamide 250mg as a companion treatment.